AARTI PHARMALABS LIMITED
AARTIPHARM · General/Diversified · NSE
₹707
Current Market Price
Fair Value (DCF)
₹414
Margin of Safety
-41.5%
Updated 2d ago
YieldIQ Score
53/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
36%
ROE
—
Debt/Equity
0.33
WACC
11.1%
Market Cap
₹6,407 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.2%
Return on capital employed
EV / EBITDA
17.5×
Enterprise multiple
Debt / EBITDA
1.0×
Leverage vs earnings
Interest Coverage
14.4×
EBIT covers interest
Current Ratio
2.01×
Short-term liquidity
Asset Turnover
0.72×
Revenue per ₹ of assets
Revenue CAGR (3Y)
20.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹706.7
Bear case
₹216.1
MoS -227.0%
Base case
₹413.73
MoS -70.8%
Bull case
₹478.96
MoS -47.5%
Ratio Trends
AARTIPHARM · last 4 annual periods
ROE
13.7%
ROCE
19.7%
Operating Margin
—
Debt / Equity
0.21×
PE
58.3×
EV / EBITDA
7.8×
Historical Financials
AARTIPHARM · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹1192 Cr | ₹485 Cr | ₹506 Cr | ₹2086 Cr | +20.5% |
| EBITDA | ₹198 Cr | ₹344 Cr | ₹391 Cr | ₹474 Cr | +33.9% |
| EBIT | — | ₹64.8 Cr | ₹100 Cr | — | +15.7% |
| PAT | ₹122 Cr | ₹42.9 Cr | ₹65.3 Cr | ₹272 Cr | +30.6% |
| EPS (diluted) | — | ₹4.73 | ₹7.20 | — | +15.0% |
| CFO | ₹-43.7 Cr | ₹263 Cr | ₹216 Cr | ₹332 Cr | — |
| CapEx | ₹-141 Cr | — | — | ₹-444 Cr | — |
| FCF | ₹-185 Cr | — | — | ₹-112 Cr | — |
| Total Assets | ₹2040 Cr | ₹2231 Cr | ₹2582 Cr | ₹2906 Cr | +12.5% |
| Total Debt | ₹341 Cr | ₹214 Cr | ₹264 Cr | ₹421 Cr | +7.2% |
| Shareholders' Equity | ₹1386 Cr | ₹1558 Cr | ₹1757 Cr | ₹1990 Cr | +12.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AARTIPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| FDC FDC | — | — | Pending | 11.7% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
| SUVEN SUVEN | — | — | Pending | — | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Overvalued | 3.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AARTIPHARM in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AARTIPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AARTIPHARM →
Compare
Head-to-head with peers
Compare AARTIPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AARTIPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.